GCO · Genesco
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $42.72
Note written ·
Price against the kill line
16.9% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $42.72, on record since 11 November 2026. The shares are up 2.5% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $42.72, the highest close of the last 126 sessions (11 June 2026), would show the shares leading the S&P 500 and prove this call wrong.
Research onlyNot in the portfolio.
Key figures from the filings · Consumer Discretionary
Quarter to 1 August 2026, filed 10 September 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 530
- Revenue, change on a year (%)
- −3.0
- Gross margin (%)
- 51.4
- Operating margin (%)
- 0.7
- Free cash flow, four quarters ($M)
- 73.8
- Net cash, cash less debt ($M)
- 41.3
- Price to earnings (×)
- 9.2
- Enterprise value to sales (×)
- 0.1
All filed numbers
What Genesco reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 530 | −3.0 | 51.4 | 0.7 |
| first filed | 487 | +2.8 | 47.0 | −3.2 |
| first filed | 800 | +7.2 | 45.9 | 6.4 |
| first filed | 616 | +3.3 | 46.8 | 1.4 |
| first filed | 546 | +4.0 | 45.8 | −2.6 |
| first filed | 474 | +3.6 | 46.7 | −5.9 |
| Pre-tax income ($M) | 3.4 |
| Net income ($M) four quarters: 41.6 | 3.5 |
| Diluted shares, change on a year (%) against the quarter to 2 August 2025 | +6.1 |
| Operating cash flow ($M) | 134 |
| Capital spending ($M) | 60.2 |
| Free cash flow ($M) | 73.8 |
| Cash and short-term investments ($M) | 57.1 |
| Debt ($M) long-term debt | 15.8 |
| Net cash, cash less debt ($M) | 41.3 |
| Deferred revenue ($M) at 31 January 2026, filed 25 March 2026; +22.0% on a year | 6.1 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 39.7 |
| Inventory ($M) | 540 |
| Shareholders' equity ($M) | 557 |
| Market value ($M) | 384 |
| Enterprise value, market value plus net debt ($M) | 343 |
| Enterprise value to sales (×) | 0.1 |
| Enterprise value to operating income (×) | 7.1 |
| Price to earnings (×) | 9.2 |
| Price to book value (×) | 0.7 |
| Free-cash-flow yield (%) | 19.2 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 11.6% of shares outstanding sold short, 11.6 days of average trading to cover, −0.8% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $10K | $0 |
| 12 monthsfrom | $110K | $0 |
The thesis
Genesco's turnaround rests on gross margin gains outrunning soft footwear demand, and the shares are more likely to trail the S&P 500 than beat it over the next three months. The Q3 fiscal 2027 report, expected in early December, settles whether those margin gains survive an 8% inventory build. The company has not announced the date; Earnings Whispers lists 3 December 2026, and last year's Q3 report came on 4 December 2025.
The shares closed at $36.79 on 10 November 2026, 13.9% below the 52-week high of $42.72 (adjusted close) and up 3.6% over three months. The AAII investing site reported a prior close of $37.66, so the shares fell 2.3% on the day, and it gave no reason for the move. The 14-day Relative Strength Index, a momentum gauge where readings above 70 are conventionally called stretched, is 52.1, down from 72.9 on 15 October 2026.
On 3 September 2026 Genesco reported second-quarter comparable sales down 1% and cut its fiscal 2027 comparable-sales outlook to flat. Adjusted gross margin rose to 47.2%, up 140 basis points, and the adjusted operating loss narrowed to $8.3 million from $14.3 million. The adjusted earnings outlook of $2.00 to $2.40 per share was kept.
The story is well known: the proxy contest ended with all nine director nominees elected on 22 July 2026, the Wrangler footwear launch of 15 September 2026 is past, and searches of company news and SEC filings found nothing new from Genesco since the 3 September 2026 report. The next quarter's margin and inventory numbers carry the case.
Bullish and bearish views on Genesco Inc.
The bull case on Genesco Inc. (GCO), in brief: margins are improving on lower sales. The bear case: demand is flat to falling.
Bull case
- Margins are improving on lower sales. Genesco's 3 September 2026 presentation shows second-quarter adjusted gross margin of 47.2% and an adjusted operating loss of $8.3 million against $14.3 million a year earlier. Cost cuts are doing work that revenue is not.
- The earnings outlook held. The 3 September 2026 8-K kept fiscal 2027 adjusted earnings at $2.00 to $2.40 per share even as the sales view was lowered. A Q3 report that reaffirms the range would show the margin plan intact.
- Borrowing is small. Funded borrowings were $15.8 million against $57.1 million of cash at 1 August 2026, per the quarter's filing. The $22.5 million of tariff refunds received in the quarter is excluded from adjusted results and guidance.
- Company repurchases resumed. Genesco's 3 September 2026 disclosure reported 317,503 shares repurchased after 1 August 2026, with $18.8 million of authorization remaining. With about 11.1 million shares outstanding (11 June 2026), buybacks weigh more than in a larger stock.
- The shares have recovered from September. In mid-September the shares fell to $32.76, per a news summary of that month's trading; the 10 November 2026 close of $36.79 is 12.3% higher than that low.
Bear case
- Demand is flat to falling. Second-quarter comparable sales fell 1% on 3 September 2026; Journeys grew 2% and Johnston & Murphy grew 4%, while schuh, the UK banner, fell 9%. Management lowered its fiscal 2027 comparable-sales outlook from growth of 1% to 2% to flat.
- Inventory is growing faster than sales. Inventory was up 8% at 1 August 2026 while second-quarter sales fell 3%. The holiday quarter's gross margin will show whether that stock sells at full price.
- Analysts are cautious. Truist cut its target from $38 to $40 on 4 September 2026 in the wrong direction of the older figure; the cut was from $40 to $38, with a Hold rating kept. The $39.67 average target from four analysts (S&P Global via StockAnalysis, 3 October 2026) sits 7.8% above the $36.79 close. AAII reported one downgrade and no upgrades over the month to 10 November 2026 without naming the firm.
- Senior turnover continues. Parag Desai, Chief Strategy and Digital Officer, moved to part-time on 6 August 2026 with retirement effective 31 October 2026, and Jonathan Collins became chief financial officer on 3 August 2026. News searches as of 11 November 2026 show no announced successor to the strategy and digital role.
- Tariff and UK exposure. The government's Federal Circuit appeal of the tariff refund order, filed 2 June 2026, is pending, and schuh comped down 9% in both Q1 and Q2 of fiscal 2027.
Price setup
The shares closed at $36.79 on 10 November 2026 against a 52-week high of $42.72 and the September low of $32.76. The closes of $37.05 (28 October 2026), $37.42 (15 October 2026) and $36.79 show a narrow range for nearly a month. Momentum has cooled, with the 14-day Relative Strength Index at 52.1.
AAII reported the shares up 48.16% year to date as of 3 November 2026, so the year's gain is large even with the shares 13.9% under the high. Crowding evidence is limited to the near-term earnings date, about three weeks away, and the thin float of about 11.1 million shares. No SEC Form 4 insider sales or share issuance were found in news searches.
Catalysts ahead
- ~19 November 2026 (est.): Company announcement of the Q3 FY27 report date. Genesco announced its Q3 FY26 date on 19 November 2025, about two weeks ahead; a similar notice would confirm the early-December timing.
- ~3 December 2026 (est.): Q3 fiscal 2027 results (Earnings Whispers date, unconfirmed by the company). Shows whether gross margin gains survive an 8% inventory build and whether the flat comparable-sales outlook holds.
- unscheduled: Federal Circuit ruling on the appeal of the tariff refund order. Guidance assumes no further refunds, so a ruling moves earnings expectations for reasons unrelated to footwear demand.
- unscheduled: Successor or reassignment for the strategy and digital role after the 31 October 2026 retirement. The role oversees the $40 million to $50 million cost program; the choice shows how management intends to deliver it.
What would change the view
A daily close above $42.72, the highest close of the last 126 sessions (11 June 2026), would show the shares leading the S&P 500 and prove this call wrong.
What it trades with
Genesco trades with US consumer discretionary retailers, especially footwear and apparel sellers tied to teen and young-adult spending, and with the holiday-quarter read from that group. Its schuh banner adds exposure to UK consumer conditions and the pound-dollar rate. Tariff policy and the pending Federal Circuit appeal link the shares to import-cost news across footwear retail. The small share count means volume in the shares can move the price more than sector news does.
The evidence, claim by claim (8)
- Q2 FY27 comparable sales fell 1%; fiscal 2027 comparable-sales outlook cut to flat. Genesco Q2 FY2027 results release · as of
- Q2 adjusted gross margin 47.2%, up 140 basis points; adjusted operating loss $8.3 million vs $14.3 million a year earlier. Genesco Q2 FY2027 investor presentation · as of
- Fiscal 2027 adjusted per-share earnings outlook of $2.00 to $2.40 retained alongside the lower sales view. Genesco 8-K, 3 September 2026 · as of
- Truist cut its price target from $40 to $38 and kept a Hold rating. MarketBeat analyst rating log · as of
- Average analyst target $39.67 from four analysts, range $36 to $45, consensus Hold. S&P Global via StockAnalysis · as of
- Funded borrowings $15.8 million against $57.1 million cash at quarter-end; inventory up 8%. Genesco Q2 FY2027 filing · as of
- Shares closed at $36.79 versus a prior close of $37.66; one analyst downgrade and no upgrades over the past month. AAII stock update; adjusted daily closes · as of
- Shares up 48.16% year to date at $36.70 intraday, down 2.45% from a $37.62 prior close. AAII stock update · as of
Sources
- Why Genesco Inc.'s (GCO) Stock Is Up 5.34% · aaii.com ·
- Genesco to Report Third Quarter Fiscal 2026 Financial Results and Hold Conference Call on December 4 2025 · secure.businesswire.com ·
- Genesco to Report Second Quarter Fiscal 2027 Financial Results and Hold Conference Call on September 3, 2026 · genesco.gcs-web.com
Related · shared themes
CPRI
Capri Holdings
Capri Holdings' Michael Kors turnaround gives the shares a modest edge over the S&P 500 after the 30 October 2026 beat-and-raise, despite a…
CROX
Crocs
Crocs, Inc. is more likely to lead the S&P 500 over three months: a third-quarter beat and a third guidance raise lifted full-year adjusted…
CRSR
Corsair Gaming
Corsair Gaming's recovery case holds after it beat third-quarter guidance and raised its 2026 outlook on 5 November 2026; the…
EL
Estee Lauder Companies
Estée Lauder's turnaround now shows in sales as well as margins, with first-quarter organic sales up 6% and the fiscal 2027 outlook raised…
See also · stocks to watch